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Abstract
Background: The FUS-DDIT3 fusion oncogene encodes an abnormal transcription factor that has a causative role in 
the development of myxoid/round-cell liposarcomas (MLS/RCLS). We have previously identified FLT1 (VEGFR1) as a 
candidate downstream target gene of FUS-DDIT3. The aim of this study was to investigate expression of FLT1 and its 
ligands in MLS cells.
Methods: HT1080 human fibrosarcoma cells were transiently transfected with FUS-DDIT3-GFP variant constructs and 
FLT1 expression was measured by quantitative real-time PCR. In addition, FLT1, PGF, VEGFA and VEGFB expression was 
measured in MLS/RCLS cell lines, MLS/RCLS tumors and in normal adiopocytes. We analyzed nine cases of MLS/RCLS 
and one cell line xenografted in mice for FLT1 protein expression using immunohistochemistry. MLS/RCLS cell lines 
were also analyzed for FLT1 by immunofluorescence and western blot. MLS/RCLS cell lines were additionally treated 
with FLT1 tyrosine kinase inhibitors and assayed for alterations in proliferation rate.
Results: FLT1 expression was dramatically increased in transfected cells stably expressing FUS-DDIT3 and present at 
high levels in cell lines derived from MLS. The FLT1 protein showed a strong nuclear expression in cells of MLS tissue as 
well as in cultured MLS cells, which was confirmed by cellular fractionation. Tissue array analysis showed a nuclear 
expression of the FLT1 protein also in several other tumor and normal cell types including normal adipocytes. The FLT1 
ligand coding gene PGF was highly expressed in cultured MLS cells compared to normal adipocytes while the other 
ligand genes VEGFA and VEGFB were expressed to lower levels. A more heterogeneous expression pattern of these 
genes were observed in tumor samples. No changes in proliferation rate of MLS cells were detected at concentrations 
for which the kinase inhibitors have shown specific inhibition of FLT1.
Conclusions: Our results imply that FLT1 is induced as an indirect downstream effect of FUS-DDIT3 expression in MLS. 
This could be a consequence of the ability of FUS-DDIT3 to hijack parts of normal adipose tissue development and 
reprogram primary cells to a liposarcoma-like phenotype. The findings of nuclear FLT1 protein and expression of 
corresponding ligands in MLS and normal tissues may have implications for tissue homeostasis and tumor 
development through auto- or intracrine signaling.
Background
Myxoid/round-cell liposarcoma (MLS/RCLS) is one of
the most common forms of liposarcoma and accounts for
about 40% of all cases [1]. The tumor cells are character-
ized by the FET family [2]FUS-DDIT3 fusion oncogene
(also called TLS-CHOP) present in more than 90% of
cases [3-5] or the EWS-DDIT3 found in a minority of
cases [6]. The causative role of FUS-DDIT3 in the initia-
tion of MLS/RCLS and its role for the MLS-specific
t u m o r  m o r p h o l o g y  h a v e  b e e n  d e m o n s t r a t e d  i n  t r a n s -
genic mice, xenografts and with FUS-DDIT3  carrying
mesenchymal stem cells [7-9].
FUS-DDIT3 encodes a protein consisting of the N-ter-
minal half of the FUS protein juxtaposed to the DNA-
binding basic leucine zipper transcription factor DDIT3
(also known as CHOP or GADD153) [4,5]. The FUS-
DDIT3 protein acts as an abnormal transcription factor
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[10] and the development of myxoid liposarcomas is thus
regarded as a consequence of deregulated FUS-DDIT3
target genes [8,9,11]. In this study, we have investigated
the expression of the putative FUS-DDIT3 target gene
FLT1 and its encoded receptor tyrosine kinase in MLS
cells.
Methods
Cell lines
The myxoid liposarcoma cell lines MLS 402-91, MLS
1765-92, MLS 2645-94 [3,11] and human fibrosarcoma
cell line HT1080 were kept frozen in liquid nitrogen or
cultured at 37°C and 5% CO2 in RPMI 1640 medium with
HEPES buffer supplemented with 2 mM L-glutamine, 50
U/ml penicillin, 50 μg/ml streptomycin and 10% fetal
bovine serum (Invitrogen). Cell lines HT1080 FUSA-GFP,
HT1080 DDIT3-GFP and HT1080 FUS-DDIT3-GFP
were generated by plasmid transfection of HT1080 fibro-
sarcoma cells as described elsewhere [8]. G418 (200 μg/
ml) was constantly added to cell lines HT1080 FUSA-
GFP, HT1080 DDIT3-GFP and HT1080 FUS-DDIT3-
GFP to ensure stable expression of GFP constructs in the
cell population. In a growth inhibition assay, FLT1-block-
ing antibody AF 321 (R&D systems) was added to MLS
cells precultured in 4% fetal bovine serum for 14 hours in
96 well plates as described [12]. The cultures were visu-
ally analyzed by light microscopy after 72 hours of incu-
bation. Flt-1 siRNA (sc-29319), PGF siRNA (sc-44027)
and control siRNA-A (sc-37007) were transfected into
cells using the siRNA Transfection Reagent (sc-29528,
Santa Cruz Biotechnology) according to instructions sup-
plied by the manufacturer.
Quantitative real-time PCR analysis
Total RNA was prepared with the RNeasy lipid tissue kit
(Qiagen) from an abdominal subcutaneous adipose tissue
biopsies of healthy individuals and from isolated adipo-
cytes as previously described [13]. Acid guanidinium thi-
ocyanate-phenol-chloroform extraction was used to
isolate total RNA in representative tumor tissue from
patients diagnosed with myxoid liposarcoma. Total RNA
of cultured cells was isolated using QIAshredder and
RNeasy Mini Kit (Qiagen). RNA concentrations were
measured with the NanoDrop ND-1000 spectrophotom-
eter. cDNA was generated using a QuantiTect Reverse
transcription kit (Qiagen) or alternatively using oligo dT
primers and Superscript III reverse transcriptase (Invit-
rogen). Real-time PCR was performed using a 7500 Fast
real-time PCR system (Applied Biosystems) with SYBR
Green detection (Qiagen). Formation of expected PCR
products were confirmed by agarose gel electrophoresis
and melt curve analysis. Gene expression data was nor-
malized against ACTB and GAPDH expression by geo-
metric averaging [14]. Independent samples t-test was
used to compare FLT1 expression between stably trans-
fected cells. The following primer pairs were used for
quantitative real-time PCR (5'-3'): FLT1_F TCCCTTAT-
GATGCCAGCAAGT, FLT1_R CCAAAAGCCCCTCT-
TCCAA; PGF_F GTTCAGCCCATCCTGTGTCT,
PGF_R AACGTGCTGAGAGAACGTCA; VEGFA_F
CATCCTGTGTGCCCCTGA, VEGFA_R TTGTCTTG
CTCTATCTTTCTTTGG; VEGFB_F AGTGCTGTGAA
GCCAGACA, VEGFB_R GGAGTGGGATGGGTGA
TG; ACTB_F GCCGTCTTCCCCTCCATC, ACTB_R
GCCTCGTCGCCCACATAG; GAPDH_F TCAGCCG-
CATCTTCTTTTG, GAPDH_R GACTCCGACCT-
TCACCTTC.
Immunohistochemistry and immunofluorescence
Formalin-fixed paraffin embedded tissue samples were
obtained, prepared and analyzed according to routine
pathology protocols as part of clinical diagnostics at the
Sahlgrenska University Hospital, Gothenburg, Sweden.
Sections were mounted on glass slides, deparaffinated in
xylol and stained as previously described [15] with pri-
mary antibodies for FLT1 (C-17, sc-316, Santa Cruz Bio-
technology) and VEGF receptor 1 (ab2350, Abcam).
Human normal organs and various cancers tissue arrays
(Super Bio Chips) containing 59 and 60 core biopsies per
slide were stained as above. Angiosarcoma tissue sections
were used as positive controls for the FLT1 staining. Neg-
ative controls were performed by omitting primary anti-
bodies. For immunofluorescence studies, cells were
grown in flaskettes, rinsed in phosphate buffered saline
(PBS) and fixed for 20 minutes in 4% formaldehyde in
PBS. Fixed cells were stained with antiserum for FLT1 (C-
17, sc-316, Santa Cruz Biotechnology) and PGF (ab9542,
Abcam) and visualized using goat anti-rabbit Cy3-conju-
gated secondary antibodies (Dako). Slides were mounted
using Prolong Gold antifade with DAPI (Molecular
Probes) and allowed to cure overnight. Cellular fluores-
cence was imaged using a Zeiss LSM510 META confocal
microscope system.
Western blot
Cellular nuclear and cytoplasmic fractions were isolated
using a PARIS kit (Ambion) according to the instructions
by the manufacturer. Protein concentrations in fractions
were determined using a bicinchoninic acid (BCA) pro-
tein assay kit (Pierce) and diluted for equal loading on
gels. Samples were mixed with 4X LDS sample buffer
(Invitrogen), 10% 0.5 M dithiothreitol and run on NuPage
4-12% Bis-Tris gels (Invitrogen). Proteins were blotted
onto PVDF membranes (Immobilon) and probed with
antibodies for FLT1 (C-17, sc-316, Santa Cruz Biotech-
nology), Lamin A (133A2, ab8980, Abcam) and GAPDH
(mAbcam 9484, Abcam). Bands were visualized by horse-
radish peroxidase-conjugated secondary antibodies byAndersson et al. BMC Cancer 2010, 10:249
http://www.biomedcentral.com/1471-2407/10/249
Page 3 of 10
chemiluminscent detection (SuperSignal West Dura
Extended Duration Substrate, Pierce). Chemiluminscent
membranes were imaged using a LAS-4000 imaging sys-
tem (Fujifilm).
Proliferation assay
Tumor cells were seeded out in wells of black walled/clear
bottom 96-well plates (BD Falcon) and allowed to adhere
overnight. The following day, VEGFR tyrosine kinase
inhibitors (TKI) II or III (Calbiochem) were added in a
concentration range of 0 to 10 μM. After 72 hours, cells
were subjected to multiple freeze-thaw lyses at -80°C and
37°C, respectively, where after cell proliferation relative to
untreated control cells was assayed with a CyQuant Cell
Proliferation Assay Kit (Molecular Probes) using a Wallac
1420 multilabel counter (PerkinElmer). Independent
samples t-test was used to evaluate differences between
wells.
Results and Discussion
I n s p e c t i o n  o f  p r e v i o u s l y  c o l l e c t e d  m i c r o a r r a y  d a t a  [ 8 ]
identified FLT1 as a candidate downstream target gene
for FUS-DDIT3. FLT1  encodes the Fms-like tyrosine
kinase 1 (also called vascular endothelial growth factor
receptor 1, VEGFR1) reported to be involved in autocrine
growth stimulatory loops in other sarcoma types [12].
Here we report that HT1080 human fibrosarcoma cells
stably transfected with FUS-DDIT3 express FLT1 tran-
scripts more than 20 times stronger than the original
HT1080 cells (Figure 1). In addition, DDIT3-transfected
HT1080 cells showed minor but significant (< 3 times)
increase in FLT1 expression whereas HT1080 cells trans-
fected with the 5' part of FUS showed slightly downregu-
lated FLT1 expression. Quantitative PCR (QPCR) analysis
also revealed that three tested MLS-derived cell lines
expressed high levels of FLT1 transcripts, further indicat-
ing that FLT1 is expressed in FUS-DDIT3 carrying cells
(Figure 1). However, transient transfection of HT1080
cells with FUS-DDIT3 failed to induce an increased FLT1
expression during a 48 hour observation period (Addi-
tional file 1). This indicates that transcription of FLT1 is
not a direct target of FUS-DDIT3. Instead, the change in
FLT1  e x p r e s s i o n  c o u l d  b e  a n  i n d i r e c t  e f f e c t  o f  F U S -
DDIT3 expression. The FUS-DDIT3 protein has the
capacity to reprogram HT1080 cells to a liposarcoma-like
phenotype by hijacking parts of normal adipose tissue
development [8,16]. The induction of FLT1 transcription
in FUS-DDIT3 expressing cells may thus be a part of this
process. This explanation is further supported by QPCR
analyses showing prominent expression of FLT1  tran-
scripts in isolated normal adipocytes (Additional file 2).
Immunohistochemistry (IHC) analysis of human MLS
tissues from nine cases and an MLS cell line xenografted
in SCID mice showed strong, predominantly nuclear
expression of the FLT1 protein (Figure 2a). The FLT1
nuclear stained tumor cells ranged from 60-80% in the
nine investigated cases. No correlation between FLT1
staining and diagnosis (MLS or RCLS) were found.
Immunofluorescence analysis of in vitro cultured MLS-
derived cell lines 402-91 (Figure 2b) and 2645-94 (not
shown), also showed a nuclear FLT1 localization. IHC
staining of angiosarcoma tissue showed a cytoplasmic
FLT1 staining in agreement with earlier reports [17] (Fig-
ure 2a). Indistinguishable results were obtained with two
different antibodies for FLT1.
The nuclear localization of FLT1 in MLS/RCLS was
surprising since the protein is commonly reported a cyto-
plasmic or plasma membrane bound protein [18]. To fur-
ther probe the cellular distribution of the FLT1 protein,
we prepared nuclear and cytoplasmic extracts from the
MLS-derived cell line MLS 402-91. Western blot analysis
of these extracts with an FLT1 specific antibody showed
t h a t  a n t i - F L T 1  r e a c t i v e  p r o t e i n s  w e r e  e n r i c h e d  i n  t h e
nuclear fraction (Figure 2c). The western blot results thus
confirmed the nuclear localization of FLT1 protein in
MLS cells. The migration difference detected between
nuclear and cytoplasmic FLT1 (Figure 2c) could be due to
different ionic strengths of the extraction buffers used for
fractionation but may well be a result of post-transla-
tional modifications of nuclear FLT1 proteins.
These results prompted a further investigation as to
whether FLT1 has a nuclear localization in other tumor
types and in normal tissues. IHC analysis of tissue arrays
containing 59 normal and 60 tumor-derived tissues
showed a strong nuclear FLT1 expression in more than
90% of the tumor cells in 1/1 pancreatic carcinoma and in
1/3 ovary carcinomas (Figure 3a). Nuclear staining was
also observed in several normal cell types, indicating that
this localization of FLT1 is not restricted to tumor cells
(Figure 3a). Most notably, FLT1 antibodies stained the
nuclei of adipocytes, suggesting that nuclear FLT1
expression is a normal feature of this cell type. In addi-
tion, FLT1 antibodies stained the nuclei of normal skin-
derived cultured F470 fibroblasts but with a more promi-
nent cytoplasmic staining compared to the MLS cells
(Figure 3b). The observation that FLT1 has a nuclear
localization in some tissues may indicate additional, yet
unknown, functions for this protein. Nuclear expression
of FLT1 has also been reported in endothelial cells and in
these cells FLT1 activation was necessary for growth and
survival [19]. Nuclear localization of other receptor
tyrosine kinases and specific functions in this compart-
ment has previously been reported [20-23]. In MLS/
RCLS and in normal adipocytes the nuclear expression
may be important for maintenance of cell lineage/differ-
entiation through phosphorylation/activation of specific
chromatin components or transcription factors.Andersson et al. BMC Cancer 2010, 10:249
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Further inspection of array data suggested that PGF,
encoding placental growth factor (PGF), a ligand of FLT1,
is transcribed in MLS cells. Quantitative RT-PCR analysis
of MLS-derived cell lines showed that PGF expression
was elevated in these cells compared with normal adipo-
cytes (Figure 4a). The other FLT1 ligands VEGFA and
VEGFB were expressed in cultured MLS cells but to a
much lower degree than in adipocytes. In addition, the
MLS cell lines showed PGF expression detected by
immunofluorescence analysis (Figure 4b). In contrast to
MLS cell lines, three MLS tumors showed a much more
heterogenous expression of PGF, VEGFA and VEGFB but
all tumors expressed PGF to some degree (Figure 4c).
These results suggest differences of in vivo and in vitro
ligand expression. Still, in light of our results, we hypoth-
esize that autocrine circuits are operating in MLS cells.
Such autocrine loops involving FLT1 have been reported
to contribute to growth and survival of tumor cells
[12,24,25] and to regulate differentiation of normal cell
types [26,27]. We tested for the presence of a possible
FLT1 autocrine growth stimulatory loop in MLS cell line
402-91 by using an FLT1-blocking antibody reported to
inhibit the growth of cells that are dependent on FLT1
signaling [12]. Incubation with this antibody failed how-
e v e r  t o  a f f e c t  g r o w t h  o r  s u r v i v a l  o f  t h e  M L S  c e l l s .
Though, receptor-targeted antibodies may be ineffective
if the receptor and ligand interacts inside of the plasma
membrane, which could be the case here. Such intracrine
growth stimulatory circuits were recently reported for
FLT1 in mammary carcinoma cells [28]. To test for an
intracrine circuit in MLS/RCLS cells, knockdown experi-
ments using siRNAs against FLT1 and PGF mRNA were
attempted. As previously reported for knockdown experi-
ments in MLS/RCLS cells [29], we were not able to
achieve efficient knockdown of FLT1 or its ligand gene
PGF. Instead we employed two specific inhibitors of
FLT1 kinase activity (TKIs) in proliferation assays of MLS
c e l l  l i n e s .  N o n e  o f  t h e  k i n a s e  i n h i b i t o r s  c a u s e d  a n y
decrease in cell numbers within the concentration range
where they have shown specific inhibition of FLT1 activ-
ity [30,31] (Figure 5). Thus, it is not likely that FLT1 and a
probable autocrine/intracrine loop has a role in survival
Figure 1 Increased FLT1 transcription in FUS-DDIT3 expressing cell lines. Bars show mean relative FLT1 expression by quantitative real-time PCR 
analysis of three independent biological replicates compared to wild type HT1080 with FLT1 expression set to 1. The geometric mean of ACTB and 
GAPDH expression was used to normalize FLT1 expression between samples. Error bars show standard error of the mean. Asterisks indicate statistical 
significance with p < 0.01.Andersson et al. BMC Cancer 2010, 10:249
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Figure 2 Nuclear FLT1 localization in MLS tumors and cultured MLS cells. (a) Immunohistochemical analysis of FLT1 expression in tissue sections 
of a representative MLS tumor and in an MLS 402-91 SCID mouse xenograft. Brown staining indicates FLT1 expression while blue staining shows neg-
atively staining nuclei. Cytoplasmic FLT1 expression in angiosarcoma was used as a positive control. (b) FLT1 expression in cultured MLS 402-91 cells 
analyzed by immunofluorescence. The merge image shows nuclear DAPI staining in blue. Scale bar indicates 10 μm. (c) Western blot analysis of nu-
clear (N) and cytoplasmic (CP) fractions of MLS 402-91 cells. Lamin A was used as a control for the nuclear fraction and GAPDH was used as control for 
the cytoplasmic fraction.Andersson et al. BMC Cancer 2010, 10:249
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Figure 3 Nuclear FLT1 expression in malignant and normal cells. (a) Immunohistochemical analysis of FLT1 expression in cancerous and normal 
tissues. Brown staining indicates FLT1 expression while blue staining shows negatively staining nuclei. (b) Immunofluorescence analysis of FLT1 ex-
pression in cultured human fibroblasts. The merge image shows nuclear DAPI staining in blue. Scale bar indicates 10 μm.Andersson et al. BMC Cancer 2010, 10:249
http://www.biomedcentral.com/1471-2407/10/249
Page 7 of 10
Figure 4 Quantitative real-time PCR analysis of PGF, VEGFA and VEGFB expression in FUS-DDIT3 expressing cell lines and tumors. (a) Bars 
show fold difference in ligand expression compared to adipocytes with a relative expression set to 1. Error bars show standard error of the mean (b) 
Immunofluorescence analysis of PGF expression in MLS 402-91. The merge image shows nuclear DAPI staining in blue. Scale bar indicates 10 μm. (c) 
Bars show relative expression of ligand mRNA in normal adipose tissue and in three MLS tumors. The geometric mean of ACTB and GAPDH expression 
was used to normalize gene expression between samples. Error bars show standard error of the mean.Andersson et al. BMC Cancer 2010, 10:249
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or proliferation in MLS cells but may contribute to the
liposarcoma phenotype. Treatment with the TKIs gave no
effect on the expression or localization of FLT1 in the
MLS cells. Thus, the nuclear localization appears not to
be related to the phosphorylation status of FLT1.
Conclusions
We conclude that upregulation of FLT1 in MLS/RCLS is
an indirect downstream effect of the liposarcoma fusion
oncogene FUS-DDIT3 and that FLT1 is expressed as a
nuclear protein both in MLS/RCLS lipoblasts and in nor-
mal adipocytes. The nuclear expression of FLT1 in adipo-
cytes and other normal cell types suggest that this
receptor tyrosine kinase has cell type specific functions in
the nuclear compartment. Most likely these involve
maintenance of cell lineage through phosphorylation of
target proteins residing in the nucleus. The expression of
FLT1 ligand genes PGF,  VEGFA and  VEGFB  in MLS/
RCLS cells and in normal adipocytes further indicates the
presence of possible autocrine or intracrine loops. The
importance of FLT1, PGF, VEGFA and VEGFB expression
and their functions in MLS/RCLS tumor development
remain unclear but our results point out this receptor/
ligand system as operational in MLS/RCLS and as such a
potential target for intervention in this tumor type.
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coma; VEGFR1: vascular endothelial growth factor receptor 1
Additional file 1 FLT1 expression in transiently transfected cells. 
HT1080 cells were transiently transfected with a FUS-DDIT3 construct and 
FLT1 expression was analyzed by quantitative real-time PCR at time points 
indicated in the figure. GAPDH expression was used to normalize FLT1 
expression. Error bars show standard error of the mean.
Additional file 2 FLT1 expression in isolated normal adipocytes. 
Expression of FLT1 in HT1080 cells and isolated adipocytes by quantitative 
real-time PCR. The geometric mean of ACTB and GAPDH expression was 
used to normalize gene expression between samples. Error bars show stan-
dard error of the mean.
Figure 5 Proliferation of tumor cells treated with VEGFR tyrosine kinase inhibitors. Cells were treated with indicated concentrations of drugs 
for 72 hours and relative cell proliferation was assayed in comparison to untreated control cells. Bars show means of three biological replicates and 
error bars show standard error of the mean. Asterisks indicate significant inhibition of proliferation with p < 0.01.Andersson et al. BMC Cancer 2010, 10:249
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